Your session is about to expire
← Back to Search
Epinephrine Alternative
1 mg/100 µL dose of ARS-1 for Asthma
Phase 2
Waitlist Available
Research Sponsored by ARS Pharmaceuticals, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Reversible bronchoconstriction.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from baseline (timepoints 0) to 1 hour
Awards & highlights
Study Summary
This trial is testing a needle-free way to give epinephrine to people with severe asthma who aren't helped by other treatments.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
You have a condition where your airways temporarily narrow, but it can be reversed.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ from baseline (timepoints 0) to 1 hour
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from baseline (timepoints 0) to 1 hour
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Effect of ARS-1 versus Albuterol and placebo
Trial Design
4Treatment groups
Active Control
Placebo Group
Group I: 1 mg/100 µL dose of ARS-1Active Control1 Intervention
Group II: 2 mg/100 µL dose of ARS-1Active Control1 Intervention
Group III: albuterol MDI (180 mcg)Active Control1 Intervention
Group IV: placeboPlacebo Group1 Intervention
Find a Location
Who is running the clinical trial?
ARS Pharmaceuticals, Inc.Lead Sponsor
2 Previous Clinical Trials
47 Total Patients Enrolled
Sarina Tanimoto, MD, PhDStudy DirectorARS Pharmaceuticals, Inc.
1 Previous Clinical Trials
32 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger